Biogen Inc. stock gains as Morgan Stanley conference underlines pivot to immunology

Published on 09/14/2026 at 21:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biogen Inc. stock is trading near its 52-week high as of September 14, 2026, after management detailed a strategic shift toward immunology at a major healthcare conference. The company highlighted growing brands offsetting multiple sclerosis declines and a stabilized revenue base.

Fotorealistisches Biotech-Labor in Cambridge MA mit Forscherin am Mikroskop und Blick auf den Charles River — Biogen Inc. Neurowissenschaftslabor in Cambridge MA zeigt Forscherin bei Gehirngewebeanalyse unter Mikroskop ISIN US09062X1037, Illustration mit AI erstellt.

Biogen Inc. stock (ISIN US09062X1037) is trading close to its 52-week high as of September 14, 2026, with shares around USD 215 on Nasdaq, supported by a strategic pivot toward immunology that management outlined at the Morgan Stanley 24th Annual Global Healthcare Conference.

Conference spotlights shift toward immunology

According to Investing.com on September 14, 2026, Biogen used the Morgan Stanley 24th Annual Global Healthcare Conference to present a broad strategic reshaping that places immunology alongside neurology as a central growth pillar.

As Investing.com reports, management emphasized that newer brands including LEQEMBI, SKYCLARYS, ZURZUVAE and QALSODY are now more than offsetting the decline in the company’s multiple sclerosis portfolio, which has been in structural retreat for several years.

Revenue base stabilizes after years of pressure

In the same conference appearance, Biogen’s leadership stated that revenue has been more or less stable over the past three years, while arguing that the business has been stabilized and the product mix improved toward higher-growth assets, according to Investing.com on September 14, 2026.

The conference transcript indicates that Biogen highlighted VUMERITY as an exception within multiple sclerosis, with ongoing exclusivity supporting continued growth, even as other MS brands face erosion from competition and generic pressure, as noted by TradingView on September 14, 2026.

Stock trades near 52-week high and reflects turnaround hopes

Per data cited by Investing.com on September 14, 2026, Biogen shares recently traded at USD 215.56 on Nasdaq, close to a 52-week high of USD 225.80 and nearly 50% above their level a year earlier, underscoring how investors have responded to the turnaround narrative.

This positioning means the stock is roughly USD 10 below its 52-week high, giving investors a concrete sense of the distance to the recent peak and the extent of the recovery from the prior year’s trough, based on the same data from Investing.com.

Closing price and trading context

At the last completed session on September 11, 2026, Biogen stock closed at USD 217.15 on Nasdaq, up 0.8 percent from the previous close, after trading in a daily range between USD 214.71 and USD 219.76 on volume of around 1.08 million shares, according to a price snapshot for that day.